US 11497770
Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
granted A61KA61K2239/29A61K38/00
Quick answer
US patent 11497770 (Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy) held by The Regents of the University of Colorado expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of Colorado
- Grant date
- Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K2239/29, A61K38/00, A61K40/11, A61K40/31